Rahul Banerjee, MD

Articles

Dr Banerjee on Future Hopes For Bispecific Antibody Therapy in Myeloma

October 8th 2024

Rahul Banerjee, MD, FACP, discusses his hopes for the future of bispecific antibody therapy for patients with multiple myeloma.

Dr Banerjee on Deciding Between CAR T-Cell Therapy and Bispecific Antibodies in Myeloma

September 24th 2024

Rahul Banerjee, MD, FACP, discusses criteria utilized in deciding between treatment with bispecific antibodies and CAR T-cell therapy in multiple myeloma.

Dr Banerjee on the Benefit of Bispecific Antibody Dose Reduction in Multiple Myeloma

September 16th 2024

Rahul Banerjee, MD, FACP, discusses clinical benefits derived when reducing the dosing of bispecific antibodies in the management of multiple myeloma.

Dr Banerjee on the Impact of Dose Modification Studies in Multiple Myeloma

September 13th 2024

Rahul Banerjee, MD, FACP, discusses the clinical impact of dose modification studies on the treatment of patients with multiple myeloma.

Dr Banerjee on Various Dosing Schedules of Bispecific Antibodies in Myeloma

August 29th 2024

Rahul Banerjee, MD, FACP, discusses the ongoing investigation into different dosing schedules of bispecific antibodies in multiple myeloma.

Dr Banerjee on Selecting Between Bispecific and CAR T-Cell Treatments in Myeloma

August 16th 2024

Rahul Banerjee, MD, FACP, discusses factors that may inform treatment selection when choosing between bispecific antibodies and CAR T-cell therapies in multiple myeloma

Dr Banerjee on the Evolving Multiple Myeloma Treatment Paradigm

August 6th 2024

Rahul Banerjee, MD, FACP, discusses key takeaways from his presentation at an OncLive State of the Science Summit on multiple myeloma.

Improving CAR T-Cell Therapy in Multiple Myeloma

July 2nd 2024

Rahul Banerjee, MD, FACP, of Fred Hutchinson Cancer Center, discusses strategies to improve the benefits of CAR T-cell therapy in multiple myeloma.

Dr Banerjee on Nivolumab Use After CAR T-Cell Therapy Progression in Myeloma and NHL

February 24th 2024

Rahul Banerjee, MD, FACP, discusses the use of nivolumab in multiple myeloma or non-Hodgkin lymphoma after progression following CAR T-cell therapy.

Trouble With the Curve: Beyond the Basics With Kaplan-Meier

April 15th 2022

Rahul Banerjee, MD, discusses how to navigate the obstacles in interpreting Kaplan-Meier curves.

Dr. Banerjee on the Rationale to Create a Supportive Mobile Health App for CAR T-Cell Therapy

December 23rd 2021

Rahul Banerjee, MD, discusses the rationale to create a supportive mobile health companion app for CAR T-cell therapy recipients and their caregivers ​to use throughout the therapeutic process.

Prepping for Your Invited Oral Presentation

June 29th 2020

Breaking down your oral presentation into specific content-related and delivery-related domains can help you remember what to rehearse and what to include.